Results 161 to 170 of about 21,140 (245)

Microinjection of Naltrexone into the Central, but not the Basolateral, Amygdala Blocks the Anxiolytic Effects of Diazepam in the Plus Maze [PDF]

, 2005
Paul Burghardt, Marlene A. Wilson
openalex   +1 more source

Peripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K⁺ Channel Pathway. [PDF]

Metabolites
Ortiz MI, Cariño-Cortés R, Fernández-Martínez E, Muñoz-Pérez VM, Castañeda-Hernández G, González-García MP.   +5 more
europepmc   +1 more source

Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial.

JAMA Intern Med
Magane KM, Dukes KA, Fielman S, Palfai TP, Regan D, Cheng DM, Lee H, Kraemer KL, Bullard MJ, Chen CA, Samet JH.   +10 more
europepmc   +1 more source

In VivoActivation of a Mutant μ-Opioid Receptor by Naltrexone Produces a Potent Analgesic Effect But No Tolerance: Role of μ-Receptor Activation and δ-Receptor Blockade in Morphine Tolerance [PDF]

, 2005
Sabita Roy, Xiaohong Guo, Jennifer Kelschenbach, Yuxiu Liu, Horace H. Loh   +4 more
openalex   +1 more source

Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter]. [PDF]

Drug Des Devel Ther
Lyu YS, Ahn H, Hong S, Park CY.
europepmc   +1 more source

CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE? [PDF]

, 2005
Gabriel Rubio, G. Ponce, Roberto Rodríguez‐Jiménez, Miguel Ángel Jiménez‐Arriero, Janet Hoenicka, Tomás Palomo   +5 more
openalex   +1 more source

LOW-DOSE NALTREXONE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

, 2003
Revital Kariv, Eliza Tiomny, Roman Grenshpon, Galit Waisman, Zamir Halpern   +4 more
openalex   +1 more source

Side effects of naltrexone observed in frequent tanners: Could frequent tanners have ultraviolet-induced high opioid levels? [PDF]

, 2005
Mandeep Kaur, Anthony Liguori, Alan B. Fleischer, Steven R. Feldman   +3 more
openalex   +1 more source

Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC). [PDF]

Health Justice
Clayman N, Eamranond P, Hanks H, Mitcheff M, RappaMannion L, York D, Mattis P, Guinen H, Carp A, Olson L, Bell K, Shahi L, Saunders E, Lee J, Marsch L.   +14 more
europepmc   +1 more source

Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol

, 2004
U. Breyer-Pfaff, Karl Nill
openalex   +1 more source